NCT06195670View on ClinicalTrials.gov

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

CRCMetastatic Colorectal CancerMetastatic Colorectal Adenocarcinoma

Interventions

DRUG

Experimental

SCRT: 5\*5Gy for 5 days, after a one-week rest, with fruquintinib plus sintilimab followed; Fruquintinib: qd po, 4mg/d, 2weeks on/1 week off, q3w; Sintilimab: intravenous infusion, 200mg, on day 1, q3w.

DRUG

Active Comparator

Capecitabine: bid po, 1000mg/m², on days 1-14, q3w; Bevacizumab: intravenous infusion, 7.5mg/kg, on day 1, q3w.

Trial Locations (1)

310022

Ji Zhu, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER

NCT06195670 - Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | Biotech Hunter | Biotech Hunter